Roivant Sciences went public via a SPAC merger with Montes Archimedes Acquisition in a $7.3bn deal.

Roivant Sciences, a biopharmaceutical and healthcare technology company, went public via a SPAC merger with Montes Archimedes Acquisition, a special purpose acquisition company sponsored by Patient Square Capital, in a $7.3bn deal. The transaction includes a fully committed $200m PIPE financing from Fidelity Management & Research Company, Eventide Asset Management, Suvretta Capital, RTW Investments, Viking Global Investors, SoftBank Group, Sumitomo Dainippon Pharma and Palantir Technologies. “Roivant was founded to address inefficiencies in the traditional pharma model. As we begin our life as a public company, we now have the opportunity to accelerate that vision and create significant value for patients, shareholders, and society. I would like to thank our new investors for their support as we continue to advance transformational medicines and novel modalities," Matthew Gline, Roivant CEO.